Total Valuation
Cardiff Oncology has a market cap or net worth of €66.21M. The enterprise value is €54.85.
Market Cap€66.21M
Enterprise Value€54.85
Share Statistics
Cardiff Oncology has 77,795,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,795,250
Owned by Insiders2.89%
Owned by Institutions9.33%
Financial Efficiency
Cardiff Oncology’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -105.93%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.74
Return on Invested Capital (ROIC)-105.93%
Return on Capital Employed (ROCE)-1.08
Revenue Per Employee19.13K
Profits Per Employee-1.48M
Employee Count31
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiff Oncology is ―. Cardiff Oncology’s PEG ratio is 0.15.
PE Ratio―
PS Ratio316.73
PB Ratio4.14
Price to Fair Value4.14
Price to FCF-4.95
Price to Operating Cash Flow-1.57
PEG Ratio0.15
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 593.00K and earned -45.85M in profits. Earnings per share was -0.69.
Revenue593.00K
Gross Profit593.00K
Operating Income-48.96M
Pretax Income-45.85M
Net Income-45.85M
EBITDA-44.95M
Earnings Per Share (EPS)-0.69
Cash Flow
In the last 12 months, operating cash flow was -40.85M and capital expenditures -62.00K, giving a free cash flow of -40.92M billion.
Operating Cash Flow-40.85M
Free Cash Flow-40.92M
Free Cash Flow per Share-0.53
Dividends & Yields
Cardiff Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.90
52-Week Price Change-56.37%
50-Day Moving Average0.84
200-Day Moving Average1.44
Relative Strength Index (RSI)53.17
Average Volume (3m)254.00
Important Dates
Cardiff Oncology upcoming earnings date is Oct 29, 2026, After Close (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Cardiff Oncology as a current ratio of 3.67, with Debt / Equity ratio of 1.72%
Current Ratio3.67
Quick Ratio3.67
Debt to Market Cap0.00
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiff Oncology has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cardiff Oncology EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -4.51.
EV to Sales288.68
EV to EBITDA-3.81
EV to Free Cash Flow-4.51
EV to Operating Cash Flow-4.51
Balance Sheet
Cardiff Oncology has €34.52M in cash and marketable securities with €457.00K in debt, giving a net cash position of €34.06M billion.
Cash & Marketable Securities€34.52M
Total Debt€457.00K
Net Cash€34.06M
Net Cash Per Share€0.44
Tangible Book Value Per Share€0.68
Margins
Gross margin is 100.00%, with operating margin of -8256.32%, and net profit margin of -7732.04%.
Gross Margin100.00%
Operating Margin-8256.32%
Pretax Margin-7732.04%
Net Profit Margin-7732.04%
EBITDA Margin-7579.60%
EBIT Margin-7732.04%
Analyst Forecast
The average price target for Cardiff Oncology is €3.43, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€3.43
Price Target Upside412.13% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-13.17%
EPS Growth Forecast37.33%